Active	Status	Sponsor type	Region	Phase	Filter
2 Active 8 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
larazotide (AT1001) / 9 Meters Biopharma
NCT05022303: AT1001 for the Treatment of COVID-19 Related MIS-C	Terminated	2	12	US	Larazotide Acetate, AT1001, Placebo	Massachusetts General Hospital	Covid19, Multisystem Inflammatory Syndrome in Children	05/24	05/24
NCT05747534: AT1001 for the Treatment of Long COVID	Recruiting	2	48	US	Larazotide Acetate, AT1001, Placebo	Massachusetts General Hospital	Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19	03/25	03/26